Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 3Stomach Neoplasms 2Neoplasms 2Rectal Neoplasms 1Rectal Diseases 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Metastatic Adenocarcinoma of the Pancreas 1Intestinal Neoplasms 1Intestinal Diseases 1Gastrointestinal Neoplasms 1Gastrointestinal Diseases 1Digestive System Neoplasms 1Digestive System Diseases 1Colonic Neoplasms 1Colonic Diseases 1Burkitt Lymphoma 1Adenocarcinoma Of Esophagus 1Adenocarcinoma 1

Interventions

trastuzumab deruxtecan 1repotrectinib 1pralsetinib 1encorafenib 1durvalumab 1Standard of Care 1Oxaliplatin 1Levoleucovorin 1Leucovorin 1Irinotecan 1Fluorouracil 1Cetuximab 1Capecitabine 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has announcements × Gastrointestinal Neoplasms × Leucovorin × Clear all
NCT04607421 2025-08-14

A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer

Pfizer

Phase 3 Active not recruiting
831 enrolled 2 FDA
Gastrointestinal

Colonic Diseases, Colonic Neoplasms, Digestive System Diseases, Digestive System Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Intestinal Diseases, Intestinal Neoplasms, Neoplasms, Rectal Diseases, Rectal Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡